Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	19.17	19.96	24.57	39.88	45.28	27.35
Short-Term Investments	72.39	70.79	89.02	79.23	172.29	164.07
Cash & Short-Term Investments	91.56	90.75	113.59	119.11	217.57	191.41
Cash Growth	-8.27%	-20.11%	-4.63%	-45.26%	13.66%	253.61%
Receivables	6.21	5.57	12.36	0.3	0.48	0.62
Prepaid Expenses	-	-	-	9.45	13.5	13
Total Current Assets	97.77	96.32	125.95	128.86	231.55	205.03
Property, Plant & Equipment	2.65	3.05	3.85	5.48	3.78	4.77
Long-Term Investments	79.07	60.61	90.3	62.77	12.24	34.24
Other Intangible Assets	-	-	-	-	6.97	7.05
Other Long-Term Assets	0.21	0.49	0.22	0.3	0.05	0.12
Total Assets	179.69	160.46	220.33	197.41	254.6	251.21

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	15.52	13.16	4.69	8.88	10.35	9.99
Accrued Expenses	4.59	7.41	7.76	10.86	8.2	7.37
Current Portion of Leases	0.59	0.55	0.48	0.43	0.68	0.72
Current Unearned Revenue	3.98	3.94	3.89	-	-	-
Other Current Liabilities	3.57	3.58	14.77	10.79	2.7	4.85
Total Current Liabilities	28.24	28.65	31.6	30.95	21.94	22.93
Long-Term Leases	1.26	1.57	2.12	3.07	1.57	2.17
Long-Term Unearned Revenue	14.31	16.17	20.04	-	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	0.37	0.37
Other Long-Term Liabilities	11.3	11	11.02	6.2	33.1	28.4
Total Liabilities	55.11	57.38	64.77	40.23	56.98	53.87

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	1,134	1,070	1,058	928.08	880.83	792.97
Retained Earnings	-1,009	-967.78	-902.86	-770.8	-682.32	-595.41
Comprehensive Income & Other	-0.3	0.61	0.1	-0.11	-0.9	-0.22
Shareholders' Equity	124.58	103.08	155.55	157.18	197.62	197.34
Total Liabilities & Equity	179.69	160.46	220.33	197.41	254.6	251.21

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.85	2.12	2.6	3.5	2.25	2.89
Net Cash (Debt)	168.77	149.25	201.3	178.38	227.56	222.76
Net Cash Growth	-5.46%	-25.86%	12.85%	-21.61%	2.15%	457.17%
Net Cash Per Share	1.31	1.22	2.60	2.56	3.49	3.93
Filing Date Shares Outstanding	147.2	120.6	107.92	70.93	66.69	61.28
Total Common Shares Outstanding	139.82	120.5	107.85	70.89	66.69	61.23
Working Capital	69.52	67.67	94.36	97.9	209.61	182.1
Book Value Per Share	0.89	0.86	1.44	2.22	2.96	3.22
Tangible Book Value	124.58	103.08	155.55	157.18	190.65	190.29
Tangible Book Value Per Share	0.89	0.86	1.44	2.22	2.86	3.11
Machinery	-	-	-	4.97	4.01	3.61
Leasehold Improvements	-	-	-	0.82	1.12	1.12

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error